

Revolutionizing the effect of *Azadirachta indica* extracts on edema induced changes in C-reactive protein and interleukin-6 in albino rats: *in silico* and *in vivo* approach

A. AMMARA¹, A. SOBIA¹, Z. NUREEN¹, A. SOHAIL², S. ABID¹, T. AZIZ³, M.A. NAHAA⁴, S.J. REWAA⁵, M.J. AHELLAH⁵, S.A.A. NOUF⁶, A.S. NEHAD⁷, Y.S. MANAL⁷, A.A. AMNAH⁸, A. MAJID⁹, S.A. ABDULHAKEEM⁹, S.D. ANAS¹⁰, A. SAAD¹¹

¹Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Punjab, Pakistan

²Department of Poultry Production, Faculty of Animal Production & Technology, University of Veterinary and Animal Sciences, Lahore, Pakistan

³Department of Agriculture University of Ioannina Arta, Greece

⁴Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

⁵Department of Biology, College of Science, University of Jeddah, Jeddah, Saudi Arabia

⁶Department of Biology, Jamoum University College, Umm Al-Qura University, Makkah, Saudi Arabia

⁷Department of Chemistry, Al Lieth University College, Umm Al-Qura University, Makkah, Saudi Arabia

⁸Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia

⁹Department of Clinical Laboratory Sciences, The Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia

¹⁰Public Health Department, Faculty of Health Sciences, Umm Al-Qura University, Makkah, Saudi Arabia

¹¹Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia

Abstract. – OBJECTIVE: The aim of the present study is to determine the *in vivo* and *in silico* anti-inflammatory effect of *Azadirachta indica* (*A. indica*) in carrageenan-induced rats and its blood biomarkers. *A. indica* (Neem) is a widely used medicinal plant across the world, especially in Pakistan. Neem leaves have been traditionally used for the synthesis of drugs and treatment of a wide variety of diseases.

MATERIALS AND METHODS: In this study, sixty albino rats (160-200 g) were divided into 4 groups: control (group I), standard (group II), ethanolic and aqueous (group III and IV) at doses of 50, 100, 200 and 400 mg/kg.

RESULTS: Ethanolic and aqueous extracts showed maximum inhibition in paw size at the 5th hour (400 mg/kg). Similarly, biomarkers measured, including Interleukin-6 and C-reactive protein, exhibited significant anti-inflammatory activity at the highest dose of 400 mg/kg in both experimental groups but were more distinct in the group treated with ethanolic extracts. Correlation between C-reactive protein (CRP) and interleukin-6 (IL-6) showed positive correlation in group III, while negative in group IV. Similarly, positive and negative correlations were observed between CRP biomarkers and paw size in group III

and IV, and the same results were also shown in the case of IL-6 and paw size. In molecular docking, the binding energy value of protein CRP and IL-1 β with the identified ligands quercetin and nimbosterol showed (-8.2 kcal/mol and -7.7 kcal/mol) the best binding affinity as compared to standard drug diclofenac with -7.0 kcal/mol binding energy respectively.

CONCLUSIONS: In conclusion, *in silico* and *in vivo* analysis revealed that the extracts of *A. indica* leaves can be used as an effective drug to manage inflammation.

Key Words:

A. indica, Albino rats, Inflammatory biomarkers, Molecular docking.

Introduction

A. indica (Neem) belongs to the Meliaceae family and is a natural source of a variety of medicinal compounds. Fruits, seeds, oil, leaves, roots, bark, and nearly all other portion of this tree possesses antiviral, anti-inflammatory, anti-ulcer,

antifungal, anti-plasmodial, antiseptic, antipyretic, and anti-diabetic properties¹⁻³. Neem leaves contain limonoids, such as nimbin, nimbanene, another ascorbic acid, n-hexacosanol, and aspartic acids that possess effective anti-inflammatory activity²⁻⁸. Medicinal plants have been used to cure various diseases for a long time⁹⁻¹⁵. In Unani, Siddha, and Ayurveda, Neem (*A. indica*) is a well-known plant utilized for various ailments, including bacterial and viral infections¹⁶. According to the World Health Organization (WHO), 60% population uses medicinal plants regularly to treat various diseases, and about 40% population is using such plants in pharmaceutical activities¹⁹. It is a natural source of many medicinal compounds that possess effective immunomodulatory, anti-inflammatory, and antihyperglycemic effects through biochemical pathways²⁰. Phenolic compounds, azadirachtin, nimbidin, alkaloids, triterpenoids, carotenoids, saponins, flavonoids, and glycosides are phytochemicals present in *A. indica* that possesses anti-inflammatory properties¹⁸.

Inflammation is the body's first immune response and a complicated biological mechanism to cell injury and vascularized tissue; however, uncontrolled, and chronic inflammation can be harmful to tissues¹⁹. Inflammation is a pathological response in which plasma fluids and blood cells assemble locally in living organisms. However, it is a defense mechanism in which complex actions and cytokines involved in the inflammatory reaction can originate, sustain, or accelerate medical problems. In recent years, medicinal plants have increased internationally in various regions of the world, and the literature showed that the immense therapeutic potential has been utilized traditionally. Medicinal plants with therapeutic properties are thought to be a useful source of unknown chemical compounds. However, inflammation-related diseases are becoming more well known, and the complexity of the currently available anti-edematous drugs poses a major cause. Therefore, the development of new, potent anti-edematous drugs with fewer serious side effects is reliable²⁻¹⁵⁻¹⁷. Carrageenan-induced edema is used to examine the role of natural products in preventing the metabolic alterations linked with acute inflammation²². Interleukin-6 (IL-6) and C-reactive protein (CRP) are basically inflammatory biomarkers, each with pro-inflammatory effects. IL-6 exhibits more potent anti-inflammatory than pro-inflammatory effects, while CRP production in the liver is stimulated by IL-6. CRP is deposited at the sites of tissue

damage and inflammation and plays an important role in inflammation²¹. Bioinformatics provides essential evidence to recognize the method of ligands binding to targets and helps to choose the best ligands for additional experimental proof. Bioinformatics utilizes computational tools to solve biological problems²⁴⁻²⁷. The goal of the present study is to evaluate the anti-inflammatory properties of ethanolic and aqueous extracts from *A. indica* leaves in a rat model, assess associated blood biomarkers, and study the phytochemical constituents of *A. indica* using *in silico* approach.

Materials and Methods

Sample Collection and Preparation of *A. indica* Extract

Fresh leaves of *A. indica* were collected from different botanical areas of Lahore and identified by the staff members of the botany department of The University of Punjab, Lahore. For plant material extraction, the cold maceration method was used²⁸.

Experimental Rats

Albino rats of either sex weighing (160-200 g) were purchased from the University of Lahore and kept in polypropylene cages in the animal house of The University of Lahore. This study was approved by the Ethics Committee of "The University of the Lahore", Lahore. Before experimental work, rats were kept in fasting condition and then were given distilled water and balanced feed²⁹.

Drugs Used in the Experiment

A. indica ethanolic and aqueous extracts were prepared at concentrations of 50, 100, 200, and 400 mg/kg and were given to group III (ethanolic extract) and group IV (aqueous extract). Diclofenac (100 mg/kg) and normal saline (10 mg/kg) were given to group I (control) and group II (standard), respectively. 100 mg/kg carrageenan was used to induce inflammation.

Procedure

Carrageenan-induced paw edema

1% carrageenan of 100 mg/kg was injected into all rat groups in the left hind paw in the sub-planter region to induce edema. Paw sizes were taken before and after the injection of carrageenan.

Grouping and Treatment Schedule

Group I was the control group, group II was the standard group, group III was treated with

ethanolic extract, and group IV was treated with Aqueous extract.

In group I (control), rats were injected with normal saline (10 ml/kg) in the sub-planter region of the hind paw. Paw size was measured. At first, paw size increased due to edema, but after 4-5 hours, it started to decrease and got normalized after 18 hours.

In group II (standard), rats were injected with diclofenac (100 mg/kg) in the sub-planter region of the hind paw. At first, paw size was increased due to edema, but after injecting diclofenac, it began to decrease and got normalized after 3 hours.

In groups III (ethanolic extract) and IV (aqueous extract), *A. indica* extracts at doses of 50, 100, 200, and 400 mg/kg was administrated.

The formula to calculate the anti-inflammatory activity is given below³⁰:

$$\% \text{ inhibition} = \frac{\text{Control mean} - \text{treated mean}}{\text{Control mean}} \times 100$$

Collection of blood samples and assessment of inflammatory biomarkers

At the end of the experiment, blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) tubes via cardiac puncture without anticoagulant and left for 10 minutes. Tubes were centrifuged at 4,000 rpm/min for 10 minutes, and obtained serum was kept at -20°C for further treatment in Eppendorf. C-reactive protein and IL-6 were examined using commercially available ELISA kits (DiaMetra, Spello, PG, Italy).

In silico anti-inflammatory activity of A. indica

Different computational tools for *in silico* studies, including ChemSkech, chimera, pymol, pyrx, depth resi-due, and discovery studio, were used to maintain the anti-inflammatory effect of *A. indica*.

Selection and Preparation of Ligands

Three ligands such as quercetin, nimbosterol, and diclofenac were selected for the docking studies. The 3D structure of the ligand molecule was assessed using the PubChem, a database of chemical molecules and their activities against the biological assays website and ChemSketch.

Protein preparation and prediction of active site

CRP and IL-1 β , two proteins involved in the inflammatory cascade, were chosen for docking studies. 3D structures were copied using Swissport

database and opened in Chimera, and one IL-1 β chain was chosen out of four. Before gathering the proteins, all extra water molecules, metals, and ions were removed. The protein structures were saved in a PDB file. In the depth residue, the active sites of IL-1 β and CRP proteins were found.

Protein-ligand docking

PyRx was used for virtual screening to find ligand molecules for a specific protein or the potential of an anti-inflammatory drug. In this technique, the target proteins CRP and IL-1 β , as well as ligand molecules, were chosen from PDB files and attached to the receptor protein's binding site. Similarly, the discovery studio tool was used in this method to create the structure of protein-ligand molecules and the 3D structure of complex for high-quality observation.

Statistical Analysis

Data were subjected to homogeneity of variance to check normality and preceded to one-way ANOVA using PROC GLM in SAS software (Cary, North Carolina, USA) (version 9.1). Duncan's multiple range test, Pearson correlation method, and Dunnett's *t*-test were used considering $p < 0.05$.

Results

The anti-inflammatory effect of *A. indica* ethanolic and aqueous extracts against paw edema was determined with the following groups: group I (control) consisted of 6 rats, treated with normal saline, group II (standard) consisted of 6 rats, treated with diclofenac, groups III and IV, both experimental groups, comprised of 48 rats, treated with *A. indica* ethanolic and aqueous extracts correspondingly, at doses of 50, 100, 200 and 400 mg/kg.

Effect of A. Indica on Paw Sizes in Rats

All groups showed a significant increase in paw edema volume injected with 1% carrageenan. Group I showed a remarkable increase in paw volume (45.17 ± 1.66 , 47.83 ± 2.29 , 55.67 ± 2.58 , 64.17 ± 1.66 , and 62.33 ± 1.67 after 1 to 5 hours of injection. While groups III and IV, treated with *A. indica* extracts at different concentrations (50, 100, 200, and 400 mg/kg), reduced paw edema at 1 to 5 hours as compared to group I, which showed an improvement in the edema volume as compared to group I. The improvement was more pronounced at the 5th hour in a dose-dependent manner with 40.11, 45.80, 48.24, and 50.13% inhibition closer to

Table I. Mean paw size and % age inhibition of paw size by groups I (control), II (standard), III (Ethanollic extract of *A. indica*) in carrageenan-induced paw edema of rats.

Treatment Groups	Reaction Time with Mean ± S.D (% inhibition) per hour				
	1-hour	2-hour	3-hour	4-hour	5-hour
Group I	45.83 ^a ± 1.74	49.17 ^a ± 1.96	57.17 ^a ± 2.71	64.50 ^a ± 2.11	61.50 ^a ± 1.98
Group II	33.67 ^d ± 1.61 (26.53%)	36.00 ^c ± 1.15 (26.78%)	37.00 ^b ± 1.46 (35.28%)	30.67 ^d ± 1.67 (52.44%)	26.50 ^d ± 0.76 (56.91%)
Dose 50 mg/kg	39.17 ^b ± 1.19 (14.53%)	40.33 ^b ± 0.71 (17.97%)	41.50 ^b ± 1.34 (27.4%)	37.83 ^b ± 0.40 (41.34%)	36.83 ^b ± 0.40 (40.11%)
Dose 100 mg/kg	37.50 ^{bc} ± 0.76 (18.17%)	37.33 ^{bc} ± 0.71 (24.07%)	39.33 ^b ± 0.80 (31.20%)	34.00 ^{cd} ± 0.45 (47.28%)	33.33 ^c ± 0.49 (45.80%)
Dose 200 mg/kg	34.50 ^{cd} ± 0.76 (24.72%)	36.33 ^c ± 1.12 (26.11%)	40.50 ^b ± 1.18 (29.1%)	37.33 ^{bc} ± 0.08 (42.12%)	31.83 ^c ± 1.11 (48.24%)
Dose 400 mg/kg	34.50 ^{cd} ± 0.76 (24.72%)	36.17 ^c ± 1.30 (26.43%)	39.83 ^b ± 1.08 (30.33%)	33.17 ^d ± 1.05 (48.57%)	30.67 ^c ± 0.67 (50.13%)
p-value	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Mean paw size and % age of paw size inhibition by groups I, II, and IV (Aqueous extract of *A. indica*) in carrageenan-induced paw edema of rats. The letters on different means differ significantly at $p < 0.05$ (^a > ^b > ^c > ^d).




Figure 1. A, Paw sizes of rats (mm) at 1- 5 hours post carrageenan injection in group I, group II, and Group III extracts of *A. indica*. B, % Inhibition of edema by *A. indica* ethanollic extracts and diclofenac against carrageenan-induced rats paw edema at the end of 1- 5 hours; analyzed by one-way ANOVA followed by DMR test. The letters on different means differ significantly at $p < 0.05$ (^a > ^b > ^c > ^d).

diclofenac treated group 56.91% as shown in Table I (Figure 1A-B). Group IV treated with

A. indica aqueous extracts showed 29.26, 32.24, 37.67 and 42.55% inhibition activity.

Table II. Mean paw size and % age of paw size inhibition by groups I, II, and IV (Aqueous extract of *A. indica*) in carrageenan-induced paw edema of rats.

Treatment Groups	Reaction Time with Mean \pm S.D (% inhibition) per hour				
	1-hour	2-hour	3-hour	4-hour	5-hour
Group I	45.83 ^a \pm 1.74	49.17 ^a \pm 1.96	57.17 ^a \pm 2.71	64.50 ^a \pm 2.11	61.50 ^a \pm 1.98
Group II	33.67 ^d \pm 1.61 (26.53%)	36.00 ^c \pm 1.15 (26.78%)	37.00 ^b \pm 1.46 (35.28%)	30.67 ^d \pm 1.67 (52.44%)	26.50 ^d \pm 0.76 (56.91%)
Dose 50 mg/kg	45.83 ^a \pm 1.30 (0%)	47.83 ^{ab} \pm 1.35 (2.72%)	47.17 ^b \pm 1.76 (17.49%)	45.83 ^b \pm 1.01 (28.9%)	43.50 ^b \pm 0.76 (29.26%)
Dose 100 mg/kg	46.00 ^a \pm 0.73 (0.37%)	48.17 ^{ab} \pm 1.01 (2.03%)	48.17 ^b \pm 1.22 (15.7%)	43.67 ^{bc} \pm 0.49 (32.29%)	41.67 ^b \pm 0.67 (32.24%)
Dose 200 mg/kg	42.83 ^a \pm 1.30 (6.54%)	44.83 ^{bc} \pm 1.14 (8.82%)	45.67 ^b \pm 1.4 (20.11%)	41.00 ^c \pm 1.34 (36.4%)	38.33 ^c \pm 0.88 (37.67%)
Dose 400 mg/kg	39.00 ^b \pm 0.97 (14.90%)	42.17 ^c \pm 0.95 (14.23%)	45.17 ^b \pm 0.95 (20.99%)	34.83 ^d \pm 1.08 (46%)	35.33 ^c \pm 0.71 (42.55%)
<i>p</i> -value	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

The significantly different means within the column differ at $p < 0.05$ ($a > b > c > d$).




Figure 2. A, Paw sizes of rats (mm) at 1- 5 hours post carrageenan injection in group I, group II, and Group IV extracts of *A. indica*. B, % Inhibition of edema by *A. indica*. aqueous extracts and diclofenac against carrageenan induced rats paw edema at end of 1- 5 hours; analyzed by one-way ANOVA followed by DMR test. The letters on different means differ significantly at $p < 0.05$ ($a > b > c > d$).

A. indica ethanolic extract (group III) showed the most pronounced effect as compared to *A. indica* aqueous extracts (group IV), as shown in Table II (Figure 2A-B).

Effect of *A. Indica* on Immunological and Biochemical Parameter

A. indica extracts significantly ($p < 0.05$) reduced the elevated levels of CRP and IL-6

in blood. CRP biomarkers values significantly differ in group III (4.70 ± 0.01) levels of CRP and IL-6 in blood. CRP bi-omarker values significantly differ in groups III and IV (7.85 ± 0.01) as compared to group I (control) with elevated levels of CRP (9.59 ± 0.20). IL-6 values also differ significantly ($p < 0.05$) at different doses in ex-tract-treated groups III (12.77 ± 0.02) and IV (15.58 ± 0.01) as compared to group I control (17.13 ± 0.10), as shown in Table III (Figure 3A-D). The most significant ($p < 0.05$) effect of both extracts was observed at dose 400 mg/kg closer to group II (standard) treated with diclofenac drug (2.43 ± 0.09 and 10.40 ± 0.07) in a dose-dependent manner, where p -value < 0.0001 .

Comparison Study of Biomarker CRP

By comparing CRP biomarker in groups III and IV doses vs. groups I and II, a significant $p < 0.001$ mean difference between treated groups at different doses were observed. Group III treated at dose 400 mg/kg vs. control and standard group has mean differences -4.8900 and 2.26667, respectively. group IV, treated at dose 400 mg/kg vs. control and standard group, has a mean difference -1.7350 and 5.42167, respectively, as shown in Table IV.

Comparison Study of Biomarker IL-6

By comparing IL-6 biomarkers at different doses, group III, treated at dose 400 mg/kg vs. control and stand-ard, has a mean difference

Table III. Effect of *A. indica* and diclofenac CRP (ng/ml) in ethanolic (group III) and aqueous extracts (group IV).

Treatment	CRP (ng/ml)		IL-6 protein (pg/ml)	
	Group III	Group IV	Group III	Group IV
Control Group	9.59 ^a ± 0.20	9.59 ^a ± 0.20	17.13 ^a ± 0.10	17.13 ^a ± 0.10
Standard Group	2.43 ^d ± 0.09	2.43 ^c ± 0.09	10.40 ^d ± 0.07	10.40 ^c ± 0.07
Dose 50 mg/kg	5.26 ^b ± 0.01	8.25 ^{bc} ± 0.01	13.16 ^b ± 0.02	15.90 ^b ± 0.02
Dose 100 mg/kg	5.15 ^b ± 0.01	8.29 ^b ± 0.10	13.16 ^b ± 0.02	15.75 ^{bc} ± 0.04
Dose 200 mg/kg	4.88 ^c ± 0.02	7.99 ^{cd} ± 0.04	12.91 ^c ± 0.02	15.75 ^{bc} ± 0.04
Dose 400 mg/kg	4.70 ^c ± 0.01	7.85 ^d ± 0.01	12.77 ^c ± 0.02	15.58 ^d ± 0.01
<i>p</i> -value	< 0.0001	< 0.0001	< 0.0001	< 0.0001

The means with different superscripts (^a > ^b > ^c > ^d > ^e) within the column differ significantly.

Table IV. Comparisons of CRP biomarker means through Dunnett’s *t*-test in groups III and IV.

Treatment comparison	Group III (Ethanolic extracts)			Significance
	Difference between means	Simultaneous 95% confidence limits		
Dose 50 vs. group I	-4.3300	-4.6666	-3.9934	***
Dose 100 vs. group I	-4.4367	-4.7732	-4.1001	***
Dose 200 vs. group I	-4.7100	-5.0466	-4.3734	***
Dose 400 vs. group I	-4.8900	-5.2266	-4.5534	***
Dose 50 vs. group II	2.82667	2.66698	2.98636	***
Dose 100 vs. group II	2.72000	2.56031	2.87969	***
Dose 200 group II	2.44667	2.28698	2.60636	***
Dose 400 vs. group II	2.26667	2.10698	2.42636	***
	Group IV (Aqueous extracts)			
Dose 50 vs. group I	-1.2950	-1.6695	-0.9205	***
Dose 100 vs. group I	-1.3417	-1.7162	-0.9672	***
Dose 200 vs. group I	-1.5983	-1.9728	-1.2238	***
Dose 400 vs. group I	-1.7350	-2.1095	-1.3605	***
Dose 50 vs. group II	5.86167	5.62359	6.09974	***
Dose 100 vs. group II	5.81500	5.57693	6.05307	***
Dose 200 group II	5.55833	5.32026	5.79641	***
Dose 400 vs. group II	5.42167	5.18359	5.65974	***

Comparison of the experimental group IV with the control and standard group, our results showed significant difference where *** = $p < 0.001$.




Figure 3. A, Level of C-reactive protein in group I (control group), group II (standard group), and group III (ethanolic group) with various treatment doses of *A. indica*. B, Level of C-reactive protein in group I (control), group II (standard), and group IV (aqueous extract) with various treatment doses of *A. indica*. C, Level of IL-6 in group I (control group), group II (standard group), and group III (ethanolic group) with various treatment doses of *A. indica*. D, Level of IL-6 in group I (control group), group II (standard group), and group IV (aqueous group) with various treatment doses of *A. indica*. The letters on different means differ significantly at $p < 0.05$ ($a > b > c > d$).

-4.35667 and 2.37500, respectively. Group IV, treated at dose 400 mg/kg vs. control and standard groups, has a mean difference -1.55000 and 5.18167, respectively, as shown in Table V.

Correlation Study

Analyzing correlation studies is crucial to understanding biological processes. Correlation analysis is frequently used to examine, quan-

tify, and analyze the correlation between observed data. Correlation was significant at $p \leq 0.05$. According to Pearson's correlation, in group III there was a negative correlation between biomarker CRP and IL-6 ($p < 0.05$) in the control and standard groups, and at all doses 50, 100, 200, and 400 mg/kg, there was a positive correlation correspondingly. In group IV, there was a strong positive correlation at higher doses

Table V. Comparisons of IL-6 biomarker means through Dunnett's *t*-test.

Treatment comparison	Group III (Ethanollic extracts)			Significance
	Difference between means	Simultaneous 95% confidence limits		
Dose 50 vs. group I	-3.96667	-4.15947	-3.77386	***
Dose 100 vs. group I	-3.97000	-4.16281	-3.77719	***
Dose 200 vs. group I	-4.21333	-4.40614	-4.02053	***
Dose 400 vs. group I	-4.35667	-4.54947	-4.16386	***
Dose 50 vs. group II	2.76500	2.63064	2.89936	***
Dose 100 vs. group II	2.76167	2.62731	2.89603	***
Dose 200 group II	2.51833	2.38397	2.65269	***
Dose 400 vs. group II	2.37500	2.24064	2.50936	***
Group IV (Aqueous extracts)				
Dose 50 vs. group I	-1.23000	-1.42917	-1.03083	***
Dose 100 vs. group I	-1.37833	-1.57751	-1.17916	***
Dose 200 vs. group I	-1.45333	-1.65251	-1.25416	***
Dose 400 vs. group I	-1.55000	-1.74917	-1.35083	***
Dose 50 vs. group II	5.50167	5.35698	5.64636	***
Dose 100 vs. group II	5.35333	5.20864	5.49802	***
Dose 200 group II	5.27833	5.13364	5.42302	***
Dose 400 vs. group II	5.18167	5.03698	5.32636	***

In comparison of the experimental group IV with the control and standard group, our results showed significant difference where *** = $p < 0.001$.

of 200 and 400 mg/kg. A positive and negative correlation was observed between IL-6 marker and paw size, where the correlation was significant at ($p < 0.05$). A positive and negative association was evident with increasing dose rates at 100, 200, and 400 mg/kg i.e., 0.02, -0.48, and 0.13 in group III and 0.82, -0.33, and 0.25 in group IV, correspondingly.

Based on the results, CRP marker and paw sizes illustrated a positive correlation of 0.25 and 0.68, in the control and standard group. At the 4th hour, there was a positive correlation at doses of 50 and 100 mg/kg as (0.30) and (0.002). However, the correlation was weakly negative at dose of 200 and strongly negative at 400 mg/kg i.e., -0.14 and -0.47, correspondingly. At the end of 4th hour, there was

a negative correlation between the biomarker IL-6 and paw sizes ($p < 0.05$) in the experimental group IV at doses 50, 100, and 200 as (-0.14), (-0.88) and (-0.71), respectively as shown in Table VI.

In Silico Analysis

The potential of *A. indica* to target the cytokines IL-1 β and CRP was examined *in silico*. The binding energy of quercetin and nimboesterol with CRP and IL-6 showed much better docking energy results as compared to the standard drug diclofenac.

Study of protein structure evaluation and ligands in the binding pocket

IL-1 β has one chain, CRP has five chains. All ligands and proteins were added to the grid box.

Table VI. Table VI. Correlation between Paw sizes, CRP and IL-6 in group III (ethanollic group) and group IV (aqueous extract).

Treatment ¹	CRP and IL-6		IL-6 and paw sizes		CRP and Paw sizes	
	Group III	Group IV	Group III	Group IV	Group III	Group IV
Control	-0.19	-0.19	0.70	0.70	0.25	0.25
Standard	-0.54	-0.54	0.02	0.02	0.68	0.68
Dose 50 mg/kg	0.51	0.75	0.37	-0.68	0.30	-0.14
Dose 100 mg/kg	0.25	-0.89	0.02	0.82	0.002	-0.88
Dose 200 mg/kg	0.95	0.81	-0.48	-0.33	-0.14	-0.71
Dose 400 mg/kg	0.91	0.84	0.13	0.25	0.47	0.08

IV (aqueous extract).




Figure 4. A, C-reactive protein and ligand molecules (a) quercetin and nimbosterol (b) diclofenac, IL-1 β protein is represented by green color, the binding pocket: orange and ligand molecules quercetin: silver, nimbosterol: sea green and diclofenac green as shown in (B). Interlukin-1 β and ligand molecules (a) quercetin and nimbosterol (b) diclofenac.

CRP and IL-1beta with ligand molecules interaction

In Figure 4A, CRP is represented by golden color and the binding pocket with purple color and ligand molecules. Quercetin is presented with grey, nimbosterol with sea green, and diclofenac with green color. In Figure 4B, IL-1 β protein is represented by green color; the binding pocket is orange; ligand molecules quercetin is silver; nimbosterol is sea green, while diclofenac is green color.

Discussion

The present study was determined to assess the *in vivo* and *in vitro* anti-inflammatory effects of

ethanolic and aqueous extract of *A. indica* plant. The medicinal systems of Ayurveda are accepted as traditional system with significant research on clinical, therapeutics and pharmacology. Carrageenan-induced paw edema is responsive to cyclooxygenase inhibitors and used to test the efficacy of non-steroidal anti-inflammatory drugs that predominantly inhibit the cyclooxygenase implicated in prostaglandin biosynthesis, protease, and lysosomes within 1 to 6 hours. This period is useful to assess the anti-inflammatory effects of medicinal plants²⁹. In a previous study³²⁻³⁴, MEAI inhibited edema during the first and second phase of inflammation by inhibiting prostaglandin release and suppressing histamine, serotonin, and bradykinin.

According to our findings, all doses of groups III (ethanolic extract) and IV (aqueous extract) have been involved in the suppression of edema. Maximum reduction was observed at 400 mg/kg, which exhibited 50.13% and 42.55% inhibition of edema and was almost effective as the standard drug diclofenac with (56.91%) inhibition. *A. indica* can suppress eicosanoid production by inhibiting both cyclooxygenase (COX) and lipoxygenase (LOX), while thymoquinone (TQ) has been exposed to reduce lipid peroxidation and *A. indica* also inhibits macrophage nitric oxide generation. As a result, it can be confirmed that a high concentration of *A. indica* components lowers inflammation, while a smaller concentration has negative effects. Results of other studies³⁵⁻³⁸ were concurrent with our findings. *A. indica* extracts contain many phytochemicals, including flavonoids, triterpenes, and tannins which are responsible for showing significant findings in anti-inflammatory activity in a dose-dependent manner. Group III showed the strongest anti-inflammatory potential. Several previous studies³⁵⁻³⁷ concluded that phytochemicals present in Neem decrease edema by suppressing the activity of STAT-1 and NF- κ B.

CRP is an acute-phase protein generated in the liver and secreted into the bloodstream in reaction to IL-6 stimulation during an inflammatory phase. The concentration of CRP in plasma increases considerably when IL-6 levels rise. We evaluated the medicinal effects of *A. indica* in the regulation of normal systematic depending on the outcomes of inflammatory biomarkers. According to earlier research, CRP plays various essential roles during an inflammatory episode. It binds to injured, necrotic, and microbial cells, increases neutrophil and macrophage phagocytosis, and activates the complement system, which aids in the maintenance of inflammation⁴⁰. In our results, group I (control) remarkably raised the levels of CRP and IL-6 biomarkers and groups III (ethanolic extract) and IV (aqueous extract) showed significant inhibition of edema at the dose of 200 mg/kg and 400 mg/kg. In groups III and IV, a higher dose of the extract (400 mg/kg) exhibited a higher inhibitory effect on IL-6 than the lower dose (50 mg/kg). For inflammation, few cells are engaged to promote the production of pro-inflammatory chemical mediators [IL, IL-6, and Tumor Necrosis Factor alpha (TNF- α)]. Nimbolide is a plant-derived phytochemical that inhibits the expression of inflammatory cytokines such as Interleukin (IL, IL-6, IL-8, and IL-12) and nu-

clear factor (TNF- α)1. In our results, there was a positive correlation between the biomarker interleukin-6 and C-reactive protein in group IV (aqueous extract). Similarly, other reports⁴⁵⁻⁴⁷ are in concurrence with our data set showing that classic and trans pathways together take part in an inflammatory condition. All those pathways are diverse. Through classical signaling in the liver, IL-6 upregulates the production of CRP, with lipolysis. IL-6 correlates with the severity of other inflammatory processes interceding inflammatory reactions.

According to our results, computational studies determined the required geometry of two molecules with identified structures. Our findings were associated with the efficiency of bioactive substances and their interactions help to stabilize protein-ligand complexes. In molecular docking studies, the protein CRP with the identified ligands quercetin and nimboesterol showed the best binding affinity -8.2 kcal/mol and -7.72 kcal/mol, and IL-1 β represented the binding affinity -4.5 kcal/mol and -3 kcal/mol. The standard drug, diclofenac with interacting protein, exhibited the binding affinity -7.02 kcal/mol and -4.4 kcal/mol. The results of this docking study confirmed the binding potential of the reported constituents of quercetin and nimboesterol with CRP and IL-1 β , which plays a chief role in anti-inflammatory activity⁴²⁻⁴⁸.

Conclusions

The use of nonsteroidal (NSAID) or steroidal (SAID) anti-inflammatory drugs could be beneficial in treating a variety of controversial disorders, but their side effects are the leading cause of acute and chronic problems. The impact of *A. indica* is a combined and synergistic reaction of several classes of phytoconstituents, rather than a single ingredient with a variety of polarities that work by blocking the COX-1 and COX-2 enzymatic activity, as well as IL-1, CRP, IL-6, and TNF- α production is inhibited. As a result, therapies based on a safe natural source mediator with fewer side effects are required, and extracts of *A. indica* leaves can be used as an effective drug to treat disorders such as inflammation.

Informed Consent

Not applicable.

Availability of Data and Materials

All the data generated in this research study has been included in the manuscript.

Authors' Contributions

Conceptualization: Ammara, Sobia, and Sohail.; methodology, Abid and Tariq.; software, Ahellah.; validation, Rewaa.; formal analysis, Nehad and Manal investigation, Nouf and Amnah.; resources, Ammara, Sobia, Nureen and Sohail.; data curation, Abid and Tariq writing—original draft preparation, Majid and Abdulhakeem.; writing-review and editing, Nahaa, Rewaa, Nehad, Nouf, Manal, Amnah, Majid, Abdulhakeem. Anas S Dabool, Saad Alghamdi; visualization, Ammara, Sobia, Nureen and Sohail; supervision, Tariq.; project administration, Nureen; funding acquisition, Nahaa.

Ethics Approval

Ethical approval for this research study was approved by the Ethical Committee Institute of Microbiology and Biotechnology (IMBB) University of Lahore under letter No. CRiMM/22/Research/145, dated 02/12/2022.

Funding

The authors would like to express their gratitude to Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2023R356), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Acknowledgments

The authors would like to express their gratitude to Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2023R356), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

ORCID ID

Abid Sarwar: 0000-0003-2105-7201
Tariq Aziz: 0000-0003-0905-8076
Nahaa M. Alotaibi: 0000-0002-1086-6719
Rewa S Jalal: 0000-0002-8372-9117
Nouf S. Al-Abbas: 0000-0002-2981-2622
Nehad. A Shaer: 0000-0002-7848-2906
Manal Y Sameeh: 0000-0001-9052-0605
Amnah A Alharbi: 0000-0001-9879-9508
Majid Alhomrani: 0000-0001-9798-0962
Abdulhakeem S Alamri: 0000-0003-3174-0434
Anas S Dabool: 0000-0001-6744-6259
Saad Alghamdi: 0000-0003-4532-9128

References

- 1) Saleem M, Tanvir M, Akhtar MF, Iqbal M, Saleem A. Antidiabetic Potential of *Mangifera indica* L. cv. Anwar Ratol Leaves: Medicinal Application of Food Wastes. *Medicina (Kaunas)* 2019; 55: 353.
- 2) Jain S, Ganeshpurkar A, Dubey N. Molecular Docking of some Neem Constituents with COX-2 and Nos: An in-silico study. *Pharmacogn Commn* 2020; 10: 134-135.
- 3) Naureen Z, Tahira F, Muhammad H, Basit Z, Abid S, Tariq A, Metab A, Abdulrahman A, Abdullah FA. In vivo and in silico analysis of inflammatory, analgesic, and antipyretic activities of citrus para-disi leaf extract. *JCCHEMS* 2023; 5813-5821.
- 4) Aziz T, Ihsan F, Ali Khan A, Ur Rahman S, Zamani GY, Alharbi M, Alshammari A, Alasmari AF. Assessing the pharmacological and biochemical effects of *Salvia hispanica* (Chia seed) against oxi-dized *Helianthus annuus* (sunflower) oil in selected animals. *Acta Biochim Pol* 2023; 70: 211-218.
- 5) Naveed M, Bukhari B, Aziz T, Zaib S, Mansoor MA, Khan AA, Shahzad M, Dabool AS, Alruways, MW, Almalki AA, Alamri AS, Alhomrani M. Green Synthesis of Silver Nanoparticles Using the Plant Extract of *Acer oblongifolium* and Study of Its Antibacterial and Antiproliferative Activity via Mathematical Approaches. *Molecules* 2022; 27: 4226.
- 6) Ahmad B, Yousafzai AM, Maria H, Khan AA, Aziz T, Alharbi M, Alsahammari A, Alasmari AF. Curative Effects of *Dianthus orientalis* against Paracetamol Triggered Oxidative Stress, Hepatic and Renal Injuries in Rabbit as an Experimental Model. *Separations* 2023; 10: 182.
- 7) Naveed M, Batool H, Rehman SU, Javed A, Makhdoom SI, Aziz T, Mohamed AA, Sameeh MY, Alruways MW, Dabool AS, Almalki AA, Alamri AS, Alhomrani M. Characterization and Evaluation of the Antioxidant, Antidiabetic, Anti-Inflammatory, and Cytotoxic Activities of Silver Nano-particles Synthesized Using *Brachychiton populneus* Leaf Extract. *Processes* 2022; 10: 1521.
- 8) Iqbal J, Khan AA, Aziz T, Ali W, Ahmad S, Rahman SU, Iqbal Z, Dabool AS, Alruways MW, Almalki AA, Alamri AS, Alhomrani M. Phytochemical Investigation, Antioxidant Properties, and In Vivo Evaluation of the Toxic Effects of *Parthenium hysterophorus*. *Molecules* 2022; 27: 4189.
- 9) Naveed M, Makhdoom SI, Rehman SU, Aziz T, Bashir F, Ali U, Alharbi M, Alshammari A, Alasmari AF. Biosynthesis and Mathematical Interpretation of Zero-Valent Iron NPs Using *Nigella sati-va* Seed Tincture for Indemnification of Carcinogenic Metals Present in Industrial Efflu-ents. *Molecules* 2023; 28: 3299.
- 10) Saleem A, Afzal M, Naveed M, Makhdoom SI, Mazhar M, Aziz T, Khan AA, Kamal Z, Shahzad M, Alharbi M, Alshammari A. HPLC, FTIR and GC-MS Analyses of *Thymus vulgaris* Phytochemicals Executing In Vitro and In Vivo Biological Activities and Effects on COX-1, COX-2 and

- Gastric Cancer Genes Computationally. *Molecules* 2022; 27: 8512.
- 11) Sana, Ur Rahman S, Zahid M, Khan AA, Aziz T, Iqbal Z, Ali W, Khan FF, Jamil S, Shahzad M, Alharbi M, Alshammari A. Hepatoprotective effects of walnut oil and *Caralluma tuberculata* against paracetamol in experimentally induced liver toxicity in mice. *Acta Biochim Pol* 2022; 69: 871-878.
 - 12) Hena Z, Mohsin S, Shafiq UR, Zafar I, Ayaz AK, Tariq A, Waqar A, Ghazala YZ, Saeed A, Muhammad S, Metab A, Abdulrahman A. Assessing the effect of walnut (*Juglans regia*) and olive (*Olea europaea*) oil against the bacterial strains found in Gut Microbiome. *Progress in Nutrition* 2022; 24: 1-10.
 - 13) Gul R, Rahmatullah Q, Ali H, Bashir A, Ayaz AK, Tariq A, Metab A, Abdulrahman A, Abdullah FA. "Phytochemical, Antimicrobial, Radical Scavenging, and In vitro biological activities of *Teucrium stockianum* leaves. *JCCHEMS* 2023; 68: 5748-5754.
 - 14) Syed WAS, Muhammad SA, Mujaddad UR, Azam H, Abid S, Tariq A, Metab A, Abdulrahman A, Abdullah FA. In-Vitro Evaluation of Phytochemicals, Heavy Metals and Antimicrobial Activities of Leaf, Stem and Roots Extracts of *Caltha palustris* var. *alba*. *JCCHEMS* 2023; 68: 5807-5812.
 - 15) Rahmani A, Almatroudi A, Alrumaihi F, Amjad AK. Pharmacological and therapeutic potential of neem (*Azadirachta indica*). *Pharmacogn Rev* 2018; 12: 250-254.
 - 16) Alyas S, Zahra N, Ahmad MI, Zahid N, Nisar A, Hafeez MM, Alam R, Parveen A, Malik A. Anti-inflammatory, antipyretic and analgesic activities of ethanol extract of *Carica papaya*. *JWB* 2020; 4: 18-23.
 - 17) Alyas S, Zahra N, Zahid N, Nisar A, Ahmad MI. Anti-inflammatory, antipyretic and analgesic activities of ethanol extract of *Eugenia jambolana* lam. *IJB* 2020; 16: 506-511.
 - 18) Dash SP, Dixit S, Sahoo S. Phytochemical, and biochemical characterizations from leaf extracts from *Azadirachta Indica*: an important medicinal plant. *Anal Biochem* 2017; 6: 2161-1009.
 - 19) Eid A, Jaradat N, Elmarzugi NA. Review of chemical constituents and traditional usage of Neem plant (*Azadirachta indica*). *PMPJ* 2017; 2: 75-81.
 - 20) Tembe-Fokunang EA, Charles F, Kaba N, Donatien G, Michael A, Bonaventure N. The Potential Pharmacological and Medicinal Properties of Neem (*Azadirachta indica* A. Juss) in the Drug Development of Phytomedicine. *JOCAMR* 2019; 7: 1-18.
 - 21) Assanga SBI, Luján LML, Gil-Salido AA, Espinoza CLL, Angulo DF, Rubio-Pino JL, Riera RB. Anti-inflammatory activity and modulate oxidative stress of *Bucida buceras* in lipopolysaccharide-stimulated RAW 264.7 macrophages and Carrageenan-induced acute paw edema in rats. *J Med Plants Res* 2017; 11: 239-252.
 - 22) Rahmouni F, Hamdaoui L, Rebai T. In vivo anti-inflammatory activity of aqueous extract of *Teucrium polium* against carrageenan-induced inflammation in experimental models. *Arch Physiol Biochem* 2017; 123: 313-321.
 - 23) Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol* 2018; 9: 1-11.
 - 24) Suganya S, Nandagopal B, Anbarasu A. Natural Inhibitors of HMG-CoA Reductase-An In Silico Approach Through Molecular Docking and Simulation Studies. *J Cell Biochem* 2017; 118: 52-57.
 - 25) Aziz T, Naveed M, Makhdoom SI, Ali U, Mughal MS, Sarwar A, Khan AA, Zhennai Y, Sameeh MY, Dablood AS, Alharbi AA, Shahzad M, Alamri AS, Alhomrani M. Genome Investigation and Functional Annotation of *Lactiplantibacillus plantarum* YW11 Revealing Streptin and Ruminococcin-A as Potent Nutritive Bacteriocins against Gut Symbiotic Pathogens. *Molecules* 2023; 28: 491.
 - 26) Aziz T, Naveed M, Sarwar A, Makhdoom SI, Mughal MS, Ali U, Yang Z, Shahzad M, Sameeh MY, Alruways MW, Dablood AS, Almalki AA, Alamri AS, Alhomrani M. Functional Annotation of *Lactiplantibacillus plantarum* 13-3 as a Potential Starter Probiotic Involved in the Food Safety of Fermented Products. *Molecules* 2022; 27: 5399.
 - 27) Aziz T, Naveed M, Jabeen K, Shabbir MA, Sarwar A, Zhennai Y, Alharbi M, Alshammari A, Alasmari AF. Integrated genome based evaluation of safety and probiotic characteristics of *Lactiplantibacillus plantarum* YW11 isolated from Tibetan kefir. *Front Microbiol* 2023; 14: 1157615.
 - 28) El-Beltagy AEFB, Abou El-Naga AM, El-Habibi ESM. Ameliorative role of neem (*Azadirachta indica*) leaves ethanolic extract on testicular injury of neonatally diabetic rats induced by streptozotocin. *Egypt J Basic Appl Sci* 2020; 7: 210-225.
 - 29) Alyas S, Zahra N, Zahid N, Nisar A, Ahmad. Anti-inflammatory, Antipyretic and Analgesic Activities of Ethanol Extract of *Eugenia jambolana* lam. *Int J Biosci* 2020; 16: 506-511.
 - 30) Choudhury SR, Cui Y, Lubecka K, Stefanska B, Iru-dayaraj J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. *Oncotarget* 2016; 7: 46545-46556.
 - 31) Nair HJ, Sasidharan S. In-vivo studies to manifest the potent anti-inflammatory and analgesic effect of the topical formulation, Pankajakasthuri ortho-herb cream/thermagel upon single application in Wistar albino rats. *PPIJ* 2021; 9: 201-208.
 - 32) Shaikh RU, Pund MM, Gacche RN. Evaluation of anti-inflammatory activity of selected medicinal plants used in Indian traditional medication system in vitro as well as in vivo. *J Tradit Complement Med* 2015; 6: 355-361.
 - 33) Sarkhel S. Evaluation of the anti-inflammatory activities of *Quillaja saponaria* Molecular saponin extract in mice. *Toxicol Rep* 2018; 3: 1-3.
 - 34) Jisha N, Vysakh A, Vijeesh V, Latha MS. Anti-inflammatory efficacy of methanolic extract of *Muntingia calabura* L. leaves in Carrageenan induced paw edema model. *Pathophysiology* 2019; 26: 323-330.
 - 35) Pise HN, Padwal SL. Evaluation of anti-inflammatory activity of *Nigella sativa*: An experimental study. *NJPPP* 2017; 7: 707-713.

- 36) Alyas S, Aman F, Zahid B, Rafique A, Hayat S, Yasin I, Khan R. Anti-inflammatory, antipyretic and antianalgesic activities of ethanolic extracts of *Momordica charantia* on albino rats. *BCSRJ* 2023; 1: 209-209.
- 37) Alyas S, Zahra N, Nisar A, Shafeeq T, Hafeez MM, Hayat S, Riaz A, Zahid B. Antiinflammatory, antipyretic and analgesic activities of ethanol extract of *Seriphidium kurramenses*. *J Pharm Res Int* 2022; 34: 45-51.
- 38) Bashir MU, Qureshi HJ, Saleem T. Comparison of anti-inflammatory activity of *nigella sativa* and diclofenac sodium in albino rats. *J Ayub Med Coll Abbottabad* 2015; 27: 523-526.
- 39) Owolabi OO, James DB, Sani I, Andongma BT, Fasanya OO, Kure B. Phytochemical analysis, anti-oxidant and anti-inflammatory potential of *FERETIA APODANTHERA* root bark extracts. *BMC Complement Altern Med* 2018; 18: 12.
- 40) Nigussie D, Makonnen E, Tufa TB, Brewster M, Legesse BA, Fekadu A, Davey G. Systematic review of Ethiopian medicinal plants used for their anti-inflammatory and wound healing activities. *J Ethnopharmacol* 2021; 276: 114179.
- 41) Sahibzada HA, Khurshid Z, Khan RS, Naseem M, Siddique KM, Mali M, Zafar MS. Salivary IL-8, IL-6 and TNF- α as potential diagnostic biomarkers for oral cancer. *Diagnostics* 2017; 7: 1-21.
- 42) Umair HI, Saliu TP, Josiah SS, Adeola A, Danjuma JB. In silico studies of bioactive compounds from selected African plants with inhibitory activity against nitric oxide synthase and arginase implicated in asthma. *Egypt J Med Hum Genet* 2021; 22: 1-16.
- 43) Alzohairy MA. Therapeutics Role of *Azadirachta indica* (Neem) and Their Active Constituents in Diseases Prevention and Treatment. *Evid Based Complement Alternat Med* 2016; 2016: 7382506.
- 44) Munier S, Larcher T, Cormier-Aline F, Soubieux D, Su B, Guigand L, Labrosse B, Cherel Y, Quéré P, Marc D, Naffakh N. A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. *J Virol* 2010; 84: 940-952.
- 45) Gallegos JLD, Moreno Treviño MG, Escalante B, Moreno-Cuevas JE. An overview of *Neem* (*Azadirachta indica*) and its potential impact on health. *J Funct Foods* 2020; 74: 1-13.
- 46) Alyas S, Yasin I, Shafique T, Zahid B, Hayat S, Shahbaz M, Khan R. Anti-inflammatory, antipyretic and analgesic activities of *Eucalyptus globulus* essential oil in albino rats. *BCSRJ* 2023; 1: 207.
- 47) Alyas S, Habib R, Shafique T, Zahid B, Hayat S, Ilyas A, Khan R. Anti-inflammatory, antipyretic and analgesic activities of chloroform extract of *Aloe barbadensis miller* in albino rats. *BCSRJ* 2023; 1: 208.
- 48) Benish R, Sobia A, Naureen Z, Sohail A, Abid S, Tariq A, Metab A, Abdulrahman A, Abdullah FA. Evaluating the influence of *Aloe barbadensis* extracts on edema induced changes in C-reactive protein and interleukin-6 in albino rats through in vivo and in silico approaches. *Act Biochem Pol* 2023; 70: 425-433.